Richard I. Murahata

  • Citations Per Year
Learn More
Intravenous administration of C. parvum following SC immunization with a tumor allograft markedly impaired the generation and expression of primary cell-mediated cytotoxicity to the immunizing alloantigens. For the inhibition to become manifest, a minimum of 4 days of in vivo exposure to C. parvum was necessary, and the effect was seen only when C. parvum(More)
The ability of iv administered BCG to antagonize immunosuppression caused by injection of the antimetabolite cytarabine (beta-cytosine arabinoside; ara-C) was investigated in C57BL/6 mice. Treatment with BCG 10 days before alloimmunization with killed L1210 tumor cells decreased spleen T-cell-mediated cytolysis against allogeneic P815Y tumor cells, as(More)
The inhibition of indirect immunofluorescence was used to detect the presence of pemphigus-like antigens in urinary proteins. Antigenic material was present in 12 of 40 urine samples obtained from 16 patients with bullous pemphigoid, cicatricial pemphigoid, or pemphigus vulgaris. Antigen could not be detected in the urine of patients with carcinoma of the(More)
BACKGROUND/AIMS The ability to anticipate skin damage and subject/patient discomfort due to the removal of adhesive materials without human testing is currently limited. While standardized laboratory methods have been developed, their ability to model and predict the interaction with relevant living substrate is imperfect. The aim of this study was to(More)
Intravenous administration of Corynebacterium parvum (C. parvum) to mice during a primary immune response against tumor alloantigens impairs their ability to generate memory cell-mediated cytotoxicity (CMC) in response to an intraperitoneal rechallenge with the same tumor alloantigens. Decreased CMC was observed in spleen and mesenteric lymph nodes, whereas(More)
BACKGROUND/PURPOSE Adhesive barriers secure medical devices to skin. Laboratory adhesion models are not predictive of in vivo performance. The objectives of these studies were to validate a novel peel force device, and to investigate relationships between barrier formulations, barrier width, subjective discomfort during barrier removal, and substrates. (More)